These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26263403)

  • 1. Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
    Floris-Moore MA; Mollan K; Wilkin AM; Johnson MA; Kashuba AD; Wohl DA; Patterson KB; Francis O; Kronk C; Eron JJ
    Antivir Ther; 2016; 21(1):55-64. PubMed ID: 26263403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
    Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
    HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
    Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
    AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Martinez E; Béniguel L; Bouchaud O; Raffi F; Molina JM; Fellahi S; Peytavin G; Marcelin AG; Kolta S; Capeau J; Gibowski S; Cardon F; Reynes J; Costagliola D;
    J Antimicrob Chemother; 2019 Sep; 74(9):2742-2751. PubMed ID: 31269208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
    Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
    HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.
    Echeverría P; Bonjoch A; Puig J; Moltó J; Paredes R; Sirera G; Ornelas A; Pérez-Álvarez N; Clotet B; Negredo E
    PLoS One; 2014; 9(2):e84676. PubMed ID: 24503952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
    ; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
    AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
    Gathe J; Andrade-Villanueva J; Santiago S; Horban A; Nelson M; Cahn P; Bogner J; Spencer D; Podzamczer D; Yong CL; Nguyen T; Zhang W; Drulak M; Quinson AM
    Antivir Ther; 2011; 16(5):759-69. PubMed ID: 21817198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
    Mobley JE; Pollard RB; Schrader S; Adler MH; Kelleher T; McLaren C
    AIDS; 1999 Jul; 13(11):F87-93. PubMed ID: 10449279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.